Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 2,394 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pancreatic Cancer Clear all

Conditions: Pancreatic Cancer
Interventions: Phase I: XB2001 250 mg, Phase I: XB2001 500 mg, Phase I: XB2001 1000 mg, Phase II: XB2001 1000 mg, Phase II: Placebo; Biological
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 30
States / cities: Tucson, Arizona • Burbank, California • Cerritos, California + 26 more

Conditions: Pancreatic Cancer
Interventions: allogeneic tumor cell vaccine, recombinant interferon alfa, sargramostim, cyclophosphamide; Biological · Drug
Lead sponsor: St. Vincent Medical Center - Los Angeles; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal, Gastrointestinal Cancer, Colo-rectal Cancer, Pancreatic Cancer, Gall Bladder Cancer, Colon Cancer, Esophageal Cancer, Stomach Cancer
Interventions: Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL), Aldesleukin; Drug · Biological
Lead sponsor: Intima Bioscience, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pancreatic Cancer
Interventions: ANO31905, AG [gemcitabine+nab-paclitaxel], mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]; Drug
Lead sponsor: Anova Innovation Limited; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Los Angeles, California • Plantation, Florida • San Antonio, Texas

Conditions: Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer
Interventions: Neoantigen specific TCR-T cell drug product; Biological
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Pancreatic Cancer
Interventions: Anamorelin Hydrochloride, Placebo; Drug
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Colorectal Cancer, Pancreatic Cancer
Interventions: BMS-813160, Nivolumab, Nab-paclitaxel, Gemcitabine, 5-fluorouracil (5-FU), Leucovorin, Irinotecan; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 21 more

Conditions: Cancer
Interventions: docetaxel, thalidomide; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pancreas Cancer, Biliary Tract Cancer, Psychological Distress, Gastrointestinal Cancer
Interventions: Psilocybin; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Gastrointestinal Cancer
Interventions: Questionnaire, Interview; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumors, Pancreatic Cancer, Non Small Cell Lung Cancer, Ovarian Cancer
Interventions: MSC-1; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Scottsdale, Arizona • Grand Rapids, Michigan • Middletown, New Jersey + 2 more

Conditions: Pancreatic Trauma, Pancreatic Duct Injury, Pancreas Necrosis, Pancreas Cyst, Pancreas; Fistula, Pancreas Abscess, Intra-Abdominal Abscess, Anastomotic Leak, Pancreas Injury
Interventions: Exploratory laparotomy; Procedure
Lead sponsor: Kern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Bakersfield, California

Conditions: Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
Interventions: ELI-002 7P; Drug
Lead sponsor: Elicio Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 28
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more

Conditions: Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors, PNET, NHL
Interventions: DCR-MYC; Drug
Lead sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Pancreatic Cancer
Interventions: Pegilodecakin, FOLFOX; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 57
States / cities: Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 49 more

Conditions: Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck, Bone Cancer, Advanced Cancer, Recurrent Disease, Metastatic Tumours
Interventions: 177Lu-3BP-227 (also called 177Lu-IPN01087); Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: End of Life, Cancer
Interventions: Receive technology-based supportive cancer care, Receive redesigned team-based supportive cancer care; Other · Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 2,996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 17
States / cities: Birmingham, Alabama • Mobile, Alabama • Duarte, California + 11 more

Conditions: Pancreatic Cancer, Gastrointestinal Neoplasms, Colon Rectal Cancer Adenocarcinoma, Esophageal Cancer, Gall Bladder Cancer, Gastric (Stomach) Cancer, Gastrooesophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatobiliary Neoplasm, Liver Carcinoma, Gallbladder Carcinoma, Bile Duct Carcinoma, Carcinoma of the Large Intestine, Anal Cancer
Interventions: Observation; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lung Cancer, Ovarian Cancer, Uterine Cancer, Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Melanoma, Breast Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Rhabdomyosarcoma, Prostate Cancer
Interventions: OmniSeq Test; Diagnostic Test
Lead sponsor: Labcorp Corporation of America Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Fort Payne, Alabama • Orange City, Florida • Stuart, Florida + 5 more

Conditions: Resectable Pancreatic Cancer, Pancreatic Ductal Carcinoma
Interventions: FOLFIRINOX, Gemcitabine/nab-Paclitaxel, Radiation therapy, Capecitabine; Drug · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage III Non-small Cell Lung Cancer, Stage I Pancreatic Cancer, Stage II Non-small Cell Lung Cancer, Stage IVB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Colon Cancer, Stage IVA Pancreatic Cancer
Interventions: Detox-B adjuvant, ras peptide cancer vaccine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Timeline: Started 1995
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Fallopian Tube Cancer, Triple Negative Breast Cancer, Multiple Myeloma, Pancreatic Ductal Adenocarcinoma
Interventions: CART-TnMUC1, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Tampa, Florida + 7 more

Conditions: Pancreatic Cancer
Interventions: bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 120 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Endocrine Neoplasia, Pancreatic Neuroendocrine Tumors, Hyperparathyroidism
Interventions: Genome Sequencing, Data Review; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

Anamorelin Study for Advanced Pancreatic Cancer

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers

Validating M.D. Anderson Symptom Inventory (MDASI-GI) in GI Cancer Patients Under Chemotherapy

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

A Retrospective Analysis of Pancreatic Injuries and Treatment Outcomes

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Permission to Collect Blood Over Time for Research

PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine

Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)